Share this article
Share this article
ResearchAndMarkets.com s offering.
The real-world evidence solutions market is expected to grow at a CAGR of 16.5% from 2020 to 2027 to reach USD 3.13 billion by 2027.
The growth in the real-world evidence solutions market is mainly attributed to the rising geriatric population and burden of chronic diseases, the shift towards value-based care, growing focus on personalized healthcare, delays in drug development and the subsequent increase in development costs, and expanding use of RWE for regulatory decision making. Moreover, growth opportunities in emerging markets; rising focus on end-to-end RWE services; and emerging roles of wearable devices, social media, and AI in RWE provide growth opportunities for players operating in the real-world evidence solutions market.
Press release content from Business Wire. The AP news staff was not involved in its creation.
AM Best Affirms Credit Ratings of UnitedHealth Group Incorporated and Most Subsidiaries; Upgrades Credit Ratings of Certain Subsidiaries
December 18, 2020 GMT
OLDWICK, N.J. (BUSINESS WIRE) Dec 18, 2020
AM Best has affirmed the Long-Term Issuer Credit Rating (Long-Term ICR) of “a-” and the Long-Term Issue Credit Ratings (Long-Term IR) of UnitedHealth Group Incorporated (UnitedHealth Group) (Minnetonka, MN) [NYSE: UNH]. AM Best also has affirmed the Short-Term Issue Credit Rating (Short-Term IR) of UnitedHealth Group. Concurrently, AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term ICRs of “a+” of the majority of the health and dental insurance subsidiaries of UnitedHealth Group, collectively referred to as UnitedHealthcare. The outlook of these Credit Ratings (ratings) is positive.
Dec 18, 2020 19:23 UTC
AM Best Affirms Credit Ratings of UnitedHealth Group Incorporated and Most Subsidiaries; Upgrades Credit Ratings of Certain Subsidiaries OLDWICK, N.J. (Business Wire)
AM Best has affirmed the Long-Term Issuer Credit Rating (Long-Term ICR) of “a-” and the Long-Term Issue Credit Ratings (Long-Term IR) of UnitedHealth Group Incorporated (UnitedHealth Group) (Minnetonka, MN) [NYSE: UNH]. AM Best also has affirmed the Short-Term Issue Credit Rating (Short-Term IR) of UnitedHealth Group. Concurrently, AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term ICRs of “a+” of the majority of the health and dental insurance subsidiaries of
It is expected that United States Specialty Pharmaceutical Market will be US$ 387 Billion by 2026.
In the United States, the Pharmaceutical market can be categories into two types of drugs Traditional as well as Specialty drugs. In recent times, Specialty drugs have gained a substantial foothold in the US market, and as estimated, it tends to gain more momentum in the upcoming years. For this, the credit goes to the companies initiatives towards Research and Developments (R&D s) of these drugs.
During the years, Specialty pharmaceutical has changed much due to speciality drugs being in the final stages of development in the United States. Speciality drugs are for rare and chronic diseases, and the drugs fall under this category are much expensive compared to traditional medications. Research has shown that a large portion of the US population was ageing and more people are prone towards chronic and rare diseases like cancer, Autoimmune, Multiple sclerosis.
Global Real World Evidence (RWE) Solutions Markets 2020-2027 - AI in RWE Provide Growth Opportunities for Players marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.